JLE

Hépato-Gastro & Oncologie Digestive

MENU

Maladies vasculaires du foie Volume 25, numéro 8, Octobre 2018

  • [1] Valla DC, Cazals-Hatem D. Vascular liver diseases on the clinical side: Definitions and diagnosis, new concepts. Virchows Archiv : an international journal of pathology 2018.
  • [2] Cazals-Hatem D., Hillaire S., Rudler M. Obliterative portal venopathy: Portal hypertension is not always present at diagnosis. J Hepatol. 2011;54:455-461. 3
  • [3] Siramolpiwat S., Seijo S., Miquel R. Idiopathic portal hypertension : natural history and long-term outcome. Hepatology. 2014;59:2276-2285. 6
  • [4] Barge S., Grando V., Nault J.C. Prevalence and clinical significance of nodular regenerative hyperplasia in liver biopsies. Liver Int. 2016;36:1059-1066. 7
  • [5] Elkrief L., Rautou P.E. Idiopathic non-cirrhotic portal hypertension: The tip of the obliterative portal venopathies iceberg? Liver Int. 2016;36:325-327. 3
  • [6] Seijo S., Reverter E., Miquel R. Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension. Dig Liver Dis. 2012;44:855-860. 10
  • [7] Bissonnette J., Garcia-Pagan J.C., Albillos A. Role of the Transjugular Intrahepatic Portosystemic Shunt in the Management of Severe Complications of Portal Hypertension in Idiopathic Noncirrhotic Portal Hypertension. Hepatology. 2016;64:224-231. 1
  • [8] Schouten J.N., Garcia-Pagan J.C., Valla D.C., Janssen H.L. Idiopathic noncirrhotic portal hypertension. Hepatology. 2011;54:1071-1081. 3
  • [9] Schouten J.N., Nevens F., Hansen B. Idiopathic noncirrhotic portal hypertension is associated with poor survival : results of a long-term cohort study. Aliment Pharmacol Ther. 2012;35:1424-1433. 12
  • [10] de Franchis R. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop : Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743-752. 3
  • [11] European Association for the Study of the Liver. Electronic address eee. EASL Clinical Practice Guidelines : Vascular diseases of the liver. J Hepatol 2016 ; 64 (1) : 179-202.
  • [12] Radomski J.S., Chojnacki K.A., Moritz M.J. Results of liver transplantation for nodular regenerative hyperplasia. The American surgeon. 2000;66:1067-1070. 11
  • [13] Dhar A., Mullish B.H., Thursz M.R. Anticoagulation in chronic liver disease. J Hepatol. 2017;66:1313-1326. 6
  • [14] Nery F, Chevret S, Condat B, et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: Results of a longitudinal study. Hepatology 2015 ; 61 (2) : 660-7.
  • [15] Francoz C., Valla D., Durand F. Portal vein thrombosis, cirrhosis, and liver transplantation. J Hepatol. 2012;57:203-212. 1
  • [16] Berzigotti A., Garcia-Criado A., Darnell A., Garcia-Pagan J.C. Imaging in clinical decision-making for portal vein thrombosis. Nat Rev Gastroenterol Hepatol. 2014;11:308-316. 5
  • [17] Tripodi A., Mannucci P.M. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365:147-156. 2
  • [18] Qi X, Han G, Fan D. Management of portal vein thrombosis in liver cirrhosis. Nat Rev Gastroenterol Hepatol 2014 ; 11 (7) : 435-46.
  • [19] Loffredo L, Pastori D, Farcomeni A, Violi F. Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis : A Systematic Review and Meta-analysis. Gastroenterology 2017 ; 153 (2) : 480-7 e1.
  • [20] Delgado M.G., Seijo S., Yepes I. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol. 2012;10:776-783. 7
  • [21] De Gottardi A., Trebicka J., Klinger C. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver Int. 2017;37:694-699. 5